TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2184649

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg, 20 mg, 30 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6103209

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 20
Study: 30939188

Group type: EXPERIMENTAL
Intervention: Spring Pillow
Number of subjects: 70

Group type: COMPARATOR
Intervention: Educational Intervention
Number of subjects: 70
Study: 28662137

Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity (average daily minutes = 24.0±18.3)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (average daily minutes = 535.2±83.8)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Physical activity frequency (average daily bouts ≥10 min = 0.64±0.74)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour frequency
Number of subjects: 504
Study: 25909356

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/elbasvir 50 mg (oral, once-daily for 12 weeks)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo (deferred therapy)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/elbasvir 50 mg
Number of subjects: 421
Study: 22814814

Group type: EXPERIMENTAL
Intervention: Ambrisentan therapy for 12 weeks
Number of subjects: 370
Study: 20387085

Group type: EXPERIMENTAL
Intervention: Philips Sonicare Elite with medium brush head
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Philips Sonicare Elite with mini brush head
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) reference toothbrush
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Elmex Sensitive toothbrush
Number of subjects: 90

Group type: COMPARATOR
Intervention: All toothbrushes
Number of subjects: 90
Study: 19468264

Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 23
Study: 17598652

Group type: EXPERIMENTAL
Intervention: 6-month cardiac rehabilitation program (45-minute training on cycle ergometer three times per week and generally improving exercises two times per week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 66
Study: 15036709

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 microg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Misoprostol 50 microg
Number of subjects: 72
Study: 11068197

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz) applied to the left dorsolateral prefrontal cortex for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz)
Number of subjects: 12
Study: 9432193

Group type: EXPERIMENTAL
Intervention: Tablets containing Noveon AA1 (10% w/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets containing Methocel K4M (10% w/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets containing Carbopol 974P (10% w/w)
Number of subjects: 0
Study: 1519779

Group type: EXPERIMENTAL
Intervention: N2O (nitrous oxide) continued after dural closure
Number of subjects: 24

Group type: COMPARATOR
Intervention: N2 (nitrogen) replaced N2O at dural closure
Number of subjects: 24
Study: 6473753

Group type: EXPERIMENTAL
Intervention: Self-instructional method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lecture instruction
Number of subjects: 0
Study: 30966831

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 80
Study: 28540411

Group type: EXPERIMENTAL
Intervention: 12‐month Assertive Community Treatment (ACT) as part of integrated care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 27751214

Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 35
Study: 25732262

Group type: EXPERIMENTAL
Intervention: VISCODERM Pearls (dietary supplement) administered 2 times a day for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VISCODERM Pearls (dietary supplement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22426799

Group type: EXPERIMENTAL
Intervention: Tongyan spray
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 20032972

Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 1.4 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 2.8 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 5.6 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh
Number of subjects: 15
Study: 18338955

Group type: EXPERIMENTAL
Intervention: Tamsulosin, 0.4 mg once daily (Group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No alpha(1)-blocker (Group B, control group)
Number of subjects: 75
Study: 15975174

Group type: EXPERIMENTAL
Intervention: Isolated soya protein (ISP) containing 68 mg/d soy isoflavones (genistein, daidzein, equol)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Milk protein placebo
Number of subjects: 23
Study: 12701051

Group type: EXPERIMENTAL
Intervention: Nervous blockade with local anesthesia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control arm (no nervous blockade)
Number of subjects: 10
Study: 10230667

Group type: EXPERIMENTAL
Intervention: Transcranial colour-coded duplex sonography (TCCS) in craniosynostosis group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Transcranial colour-coded duplex sonography (TCCS) in healthy control group
Number of subjects: 21
Study: 8744872

Group type: EXPERIMENTAL
Intervention: Health promotion activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition- and exposure-related activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Employer changes to reduce exposures to occupational hazards
Number of subjects: 0
Study: 1921739

Group type: EXPERIMENTAL
Intervention: 3.5 mg oestriol (E3) vaginal suppository, administered twice weekly for 3 weeks, then weekly for 6 months
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 344105

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 22
Study: 31126016

Group type: EXPERIMENTAL
Intervention: Nicotine content (no, low, high)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Flavor (menthol, tobacco, fruit)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Modified risk message (reduced harm, reduced carcinogen exposure)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Greater nicotine content, tobacco-flavored and reduced carcinogen exposure ECIGs
Number of subjects: 706
Study: 28774251

Group type: EXPERIMENTAL
Intervention: Dorsal extensor tendon-splitting approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dorsal extensor tendon-reflecting approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Volar A1 pulley approach
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dorsal approaches
Number of subjects: 32
Study: 26345270

Group type: EXPERIMENTAL
Intervention: Standardized measurement-based care (MBC) implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored measurement-based care (MBC) implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement-based care fidelity
Number of subjects: 0
Study: 23525931

Group type: EXPERIMENTAL
Intervention: Moderately preterm children (MP)
Number of subjects: 988
Study: 21457883

Group type: EXPERIMENTAL
Intervention: Combination of 10 mg cetirizine (CET) and 120 mg pseudoephedrine (PSE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19825188

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 114

Group type: COMPARATOR
Intervention: rLH
Number of subjects: 114
Study: 16148617

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Valsartan (160 mg)
Number of subjects: 36
Study: 12970202

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Medical
Number of subjects: 611

Group type: COMPARATOR
Intervention: AMI
Number of subjects: 611

Group type: COMPARATOR
Intervention: Coronary Angiograms
Number of subjects: 611
Study: 10574302

Group type: EXPERIMENTAL
Intervention: Group counseling sessions
Number of subjects: 396

Group type: COMPARATOR
Intervention: Individual counseling sessions
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Pretreatment motivation
Number of subjects: 396
Study: 8845685

Group type: EXPERIMENTAL
Intervention: Once-daily levobunolol 0.5%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Timolol 0.5% twice-daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Timolol 0.5% once-daily
Number of subjects: 25
Study: 2347325

Group type: EXPERIMENTAL
Intervention: Test C (decreased calf volume by lifting calves 40 cm above heart level)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Test A (resting in exercise position)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Test B (increased calf volume by venous congestion)
Number of subjects: 6
Study: 637296

Group type: EXPERIMENTAL
Intervention: Anaesthesia and operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-flow conditions
Number of subjects: 0
Study: 29537449

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.5% QD
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.0% QD
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.5% QD
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.0% BID
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.5% BID
Number of subjects: 356

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 356
Study: 27920515

Group type: EXPERIMENTAL
Intervention: ELOM-080 (3×300 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24285617

Group type: EXPERIMENTAL
Intervention: daily acute intermittent hypoxia (dAIH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: dAIH + walking
Number of subjects: 19

Group type: COMPARATOR
Intervention: daily normoxia (dSHAM)
Number of subjects: 19
Study: 22717153

Group type: EXPERIMENTAL
Intervention: Inulin supplementation (0.2 g, 0.3 g, 0.4 g, 0.5 g, and 0.6 g from day 4 to 28)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 20406355

Group type: EXPERIMENTAL
Intervention: Rough surface with microthread implants (Hexplant)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rough-surface implants (TiUnite)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hybrid surface implants (Restore)
Number of subjects: 54
Study: 18312123

Group type: EXPERIMENTAL
Intervention: Positive attachment priming
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Negative attachment priming
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Neutral attachment priming
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no priming)
Number of subjects: 169
Study: 16109990

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (annual application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride varnish
Number of subjects: 0
Study: 12145176

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9931168

Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive drugs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilation with combination treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilation with nifedipine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Endothelium-independent dilation with hydrochlorothiazide
Number of subjects: 78
Study: 7474028

Group type: EXPERIMENTAL
Intervention: Appointment reminder call (TC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of reminder call (TC) and satisfaction questionnaire
Number of subjects: 80
Study: 2193261

Group type: EXPERIMENTAL
Intervention: Topical intravaginal clindamycin phosphate (0.1%, 1.0%, and 2.0%)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Topical intravaginal clindamycin phosphate (1.0%)
Number of subjects: 62
Study: 471856

Group type: EXPERIMENTAL
Intervention: Domperidone (5 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone (5 mg i.v.) with apomorphine (0.25 mg i.v.)
Number of subjects: 0
Study: 31015124

Group type: EXPERIMENTAL
Intervention: Seroma presence (visible/highly visible)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Larger tumour size, haematoma, current smoking, and body image concerns at baseline
Number of subjects: 1149
Study: 28455465

Group type: EXPERIMENTAL
Intervention: E1 (vitamin E diffused highly cross-linked polyethylene)
Number of subjects: 67

Group type: COMPARATOR
Intervention: ArComXL (medium cross-linked polyethylene)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 67
Study: 26075212

Group type: EXPERIMENTAL
Intervention: Music aerobic exercise (MAE) for 12 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparison group (no MAE)
Number of subjects: 106
Study: 23560810

Group type: EXPERIMENTAL
Intervention: Exercise therapy starting immediately after discharge from the hospital
Number of subjects: 200

Group type: COMPARATOR
Intervention: Watchful waiting policy for the first six weeks
Number of subjects: 200
Study: 21859215

Group type: EXPERIMENTAL
Intervention: Prepartum motivation measures (global motivation, parenthood motives)
Number of subjects: 0
Study: 19037616

Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Voice exercise/behavioral treatment
Number of subjects: 90
Study: 16963664

Group type: EXPERIMENTAL
Intervention: Chest radiographs (CXRs) for early detection of lung cancer, performed annually for four years.
Number of subjects: 70000

Group type: EXPERIMENTAL
Intervention: Non-cancer abnormalities observed on CXRs.
Number of subjects: 70000

Group type: EXPERIMENTAL
Intervention: Scarring/pulmonary fibrosis, cardiac abnormalities, COPD, pleural fluid.
Number of subjects: 70000
Study: 12624520

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2, d1) and 5-FU continuous infusion (200 mg/m2/d, d1-21, q3w)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ECF (epirubicin, cisplatin and 5-FU)
Number of subjects: 50
Study: 10726720

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 8961576

Group type: EXPERIMENTAL
Intervention: Guided precatheterization information
Number of subjects: 89

Group type: COMPARATOR
Intervention: Structured precatheterization information
Number of subjects: 89
Study: 1550016

Group type: EXPERIMENTAL
Intervention: Diet A (204 patients)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Diet B (202 patients)
Number of subjects: 406
Study: 2990329

Group type: EXPERIMENTAL
Intervention: 44 081 R.P. (0.2% solution, self-administered intranasally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 0
Study: 31601170

Group type: EXPERIMENTAL
Intervention: Mindfulness-based childbirth and parenting program (8 classes of 3 hours each, plus 1 day of 7-hour silent meditation)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 74
Study: 29276121

Group type: EXPERIMENTAL
Intervention: M2a-Magnum metal-on-metal prosthesis
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ReCap resurfacing metal-on-metal prosthesis
Number of subjects: 146

Group type: COMPARATOR
Intervention: C2a ceramic-on-ceramic prosthesis
Number of subjects: 146
Study: 27658417

Group type: EXPERIMENTAL
Intervention: Continue full dose DMARDs and taper biologic therapy by 50% (Group 1)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Taper both DMARDs and biologic therapy dose by 50% (Group 2)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Taper DMARDs by 50% and stop biologic therapy (Group 3)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Stop both DMARDs and biologic therapy (Group 4)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Continue medications without change (Group 5)
Number of subjects: 157
Study: 24107267

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (O/O)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Placebo followed by OnabotulinumtoxinA (P/O)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1005
Study: 22644348

Group type: EXPERIMENTAL
Intervention: High-calcium vitamin D fortified milk (HCM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 63
Study: 20179328

Group type: EXPERIMENTAL
Intervention: Cueing training for 3 weeks at home using a prototype cueing device
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (late intervention) received cueing training in the following 3 weeks
Number of subjects: 153
Study: 17573103

Group type: EXPERIMENTAL
Intervention: Print intervention
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 239
Study: 15964292

Group type: EXPERIMENTAL
Intervention: 50 microg/day NES and 10 microg/day EE (50/10)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 50 microg/day NES and 20 microg/day EE (50/20)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 150 microg/day NES and 15 microg/day EE (150/15)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study: 11834427

Group type: EXPERIMENTAL
Intervention: GH treatment (0.03 mU/kg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study: 10794845

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ApoAI cutoff value of 1.50 g/L
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ApoAI levels
Number of subjects: 98
Study: 9289452

Group type: EXPERIMENTAL
Intervention: Pregnancy complicated by hypertension
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 62
Study: 1488158

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation in total parenteral nutrition
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard total parenteral nutrition without glutamine
Number of subjects: 45
Study: 6499703

Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Thiazide treatment in hypokalaemic participants
Number of subjects: 324
Study: 30019950

Group type: EXPERIMENTAL
Intervention: E-contact with a female homosexual partner
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: E-contact with a male homosexual partner
Number of subjects: 140

Group type: COMPARATOR
Intervention: E-contact with a heterosexual partner
Number of subjects: 140
Study: 28486817

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 54
Study: 25304690

Group type: EXPERIMENTAL
Intervention: Probiotics and/or synbiotics administration
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 23489778

Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training, practicing three WM tasks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active control group, practicing three tasks with low WM demand
Number of subjects: 66
Study: 21999705

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Alginate dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Film dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hydrofiber dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Silicone dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paraffin gauze dressing
Number of subjects: 300
Study: 17899115

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 984
Study: 16257098

Group type: EXPERIMENTAL
Intervention: Quarter dose of ETEC vaccine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 16246928

Group type: EXPERIMENTAL
Intervention: Naturally fluoridated soft water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturally fluoridated hard water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificially fluoridated soft water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificially fluoridated hard water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reference water
Number of subjects: 0
Study: 11102253

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 166
Study: 9285660

Group type: EXPERIMENTAL
Intervention: COER verapamil
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257